MA31565B1 - Estratriènes à substitution 8-bêta servant d'oestrogènes sélectivement actifs - Google Patents
Estratriènes à substitution 8-bêta servant d'oestrogènes sélectivement actifsInfo
- Publication number
- MA31565B1 MA31565B1 MA32490A MA32490A MA31565B1 MA 31565 B1 MA31565 B1 MA 31565B1 MA 32490 A MA32490 A MA 32490A MA 32490 A MA32490 A MA 32490A MA 31565 B1 MA31565 B1 MA 31565B1
- Authority
- MA
- Morocco
- Prior art keywords
- oestrogenes
- estratrienes
- selectively active
- beta substitution
- preparations
- Prior art date
Links
- 150000002164 estratrienes Chemical class 0.000 title 1
- 238000006467 substitution reaction Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 abstract 3
- 241000700159 Rattus Species 0.000 abstract 2
- 210000004291 uterus Anatomy 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000002154 estra-1,3,5(10)-trienes Chemical group 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0062—Estrane derivatives substituted in position 17 alfa not substituted in position 17 beta
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DES DÉRIVÉS ESTRA-1,3,5(10)-TRIÈNES À SUBSTITUTION 8ß DE FORMULE GÉNÉRALE (I) ; LEUR UTILISATION EN TANT QUE PRINCIPES ACTIFS PHARMACEUTIQUES, QUI PRÉSENTENT, IN VITRO, VIS-À-VIS DE PRÉPARATIONS DE RÉCEPTEURS D'¿STROGÈNES DE LA PROSTATE DE RATS, UNE AFFINITÉ SUPÉRIEURE À CELLE RELATIVE AUX PRÉPARATIONS DE RÉCEPTEURS D'¿STROGÈNES DE L'UTÉRUS DE RATS, ET AYANT DE PRÉFÉRENCE, IN VIVO, UNE ACTION PLUS MARQUÉE SUR LES OVAIRES QUE SUR L'UTÉRUS ; LEUR PRODUCTION ; LEUR UTILISATION AUX FINS THÉRAPEUTIQUES ET LEUR FORMES PHARMACEUTIQUES, DESTINÉES À ÊTRE ADMINISTRÉES, RENFERMANT CES NOUVEAUX COMPOSÉS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07075600A EP2014672A1 (fr) | 2007-07-12 | 2007-07-12 | Estratriènes 8 bêta substitués servant d'oestrogènes sélectivement actifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31565B1 true MA31565B1 (fr) | 2010-08-02 |
Family
ID=38657613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32490A MA31565B1 (fr) | 2007-07-12 | 2010-01-07 | Estratriènes à substitution 8-bêta servant d'oestrogènes sélectivement actifs |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20090029957A1 (fr) |
| EP (2) | EP2014672A1 (fr) |
| JP (1) | JP2010533152A (fr) |
| KR (1) | KR20100037593A (fr) |
| CN (1) | CN101687902B (fr) |
| AR (1) | AR067507A1 (fr) |
| AU (1) | AU2008274198A1 (fr) |
| BR (1) | BRPI0814207A2 (fr) |
| CA (1) | CA2692727A1 (fr) |
| CL (1) | CL2008002027A1 (fr) |
| CO (1) | CO6270230A2 (fr) |
| CR (1) | CR11211A (fr) |
| CU (1) | CU23885B1 (fr) |
| CY (1) | CY1113351T1 (fr) |
| DK (1) | DK2176282T3 (fr) |
| DO (1) | DOP2010000017A (fr) |
| EA (1) | EA017124B1 (fr) |
| EC (1) | ECSP109872A (fr) |
| ES (1) | ES2393942T3 (fr) |
| HN (1) | HN2010000081A (fr) |
| HR (1) | HRP20120952T1 (fr) |
| MA (1) | MA31565B1 (fr) |
| NZ (1) | NZ582490A (fr) |
| PA (1) | PA8789401A1 (fr) |
| PE (1) | PE20090825A1 (fr) |
| PL (1) | PL2176282T3 (fr) |
| PT (1) | PT2176282E (fr) |
| RS (1) | RS52541B (fr) |
| SI (1) | SI2176282T1 (fr) |
| TN (1) | TN2010000007A1 (fr) |
| TW (1) | TW200911824A (fr) |
| UA (1) | UA99918C2 (fr) |
| UY (1) | UY31220A1 (fr) |
| WO (1) | WO2009007454A2 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11072632B2 (en) * | 2011-03-25 | 2021-07-27 | UNIVERSITé LAVAL | Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10 |
| MX2019000026A (es) * | 2016-06-24 | 2019-10-30 | K&N Eng Inc | Filtros de aire compuestos y metodos de los mismos. |
| USD905747S1 (en) | 2018-04-09 | 2020-12-22 | Mitsubishi Electric Corporation | Display screen with animated graphical user interface |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10019167A1 (de) * | 2000-04-12 | 2001-10-18 | Schering Ag | Substituierte Estratriene als selektiv wirksame Estrogene |
| ATE302790T1 (de) * | 2000-04-12 | 2005-09-15 | Schering Ag | 8beta-substituierte-11beta-pentyl-und 11beta- hexyl-estra-1,3,5(10)-trienderivate |
-
2007
- 2007-07-12 EP EP07075600A patent/EP2014672A1/fr not_active Ceased
-
2008
- 2008-07-11 PE PE2008001165A patent/PE20090825A1/es not_active Application Discontinuation
- 2008-07-11 DK DK08775031.1T patent/DK2176282T3/da active
- 2008-07-11 RS RS20120516A patent/RS52541B/sr unknown
- 2008-07-11 CL CL2008002027A patent/CL2008002027A1/es unknown
- 2008-07-11 PL PL08775031T patent/PL2176282T3/pl unknown
- 2008-07-11 EP EP08775031A patent/EP2176282B1/fr active Active
- 2008-07-11 WO PCT/EP2008/059115 patent/WO2009007454A2/fr not_active Ceased
- 2008-07-11 CN CN200880024423XA patent/CN101687902B/zh not_active Expired - Fee Related
- 2008-07-11 EA EA201000097A patent/EA017124B1/ru not_active IP Right Cessation
- 2008-07-11 PA PA20088789401A patent/PA8789401A1/es unknown
- 2008-07-11 AU AU2008274198A patent/AU2008274198A1/en not_active Abandoned
- 2008-07-11 HR HRP20120952AT patent/HRP20120952T1/hr unknown
- 2008-07-11 ES ES08775031T patent/ES2393942T3/es active Active
- 2008-07-11 KR KR1020107000527A patent/KR20100037593A/ko not_active Ceased
- 2008-07-11 SI SI200830826T patent/SI2176282T1/sl unknown
- 2008-07-11 AR ARP080102978A patent/AR067507A1/es unknown
- 2008-07-11 NZ NZ582490A patent/NZ582490A/en not_active IP Right Cessation
- 2008-07-11 BR BRPI0814207-6A2A patent/BRPI0814207A2/pt not_active IP Right Cessation
- 2008-07-11 UA UAA201001369A patent/UA99918C2/ru unknown
- 2008-07-11 TW TW097126522A patent/TW200911824A/zh unknown
- 2008-07-11 US US12/171,424 patent/US20090029957A1/en not_active Abandoned
- 2008-07-11 UY UY31220A patent/UY31220A1/es not_active Application Discontinuation
- 2008-07-11 JP JP2010515526A patent/JP2010533152A/ja not_active Ceased
- 2008-07-11 CA CA 2692727 patent/CA2692727A1/fr not_active Abandoned
- 2008-07-11 PT PT08775031T patent/PT2176282E/pt unknown
-
2010
- 2010-01-07 TN TNP2010000007A patent/TN2010000007A1/fr unknown
- 2010-01-07 MA MA32490A patent/MA31565B1/fr unknown
- 2010-01-12 DO DO2010000017A patent/DOP2010000017A/es unknown
- 2010-01-12 CR CR11211A patent/CR11211A/es not_active Application Discontinuation
- 2010-01-12 CO CO10002339A patent/CO6270230A2/es active IP Right Grant
- 2010-01-12 HN HN2010000081A patent/HN2010000081A/es unknown
- 2010-01-12 CU CU20100008A patent/CU23885B1/es not_active IP Right Cessation
- 2010-01-12 EC EC2010009872A patent/ECSP109872A/es unknown
-
2012
- 2012-11-14 CY CY20121101099T patent/CY1113351T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31849B1 (fr) | Nouveaux dérivés de pyrimidine | |
| Krauwinkel et al. | The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol | |
| MA41111B1 (fr) | Compositions anticancéreuses | |
| MA31496B1 (fr) | Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c | |
| MA38576B2 (fr) | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières | |
| MA31403B1 (fr) | Polypeptides, domaines variables d'anticorps et antagonistes | |
| MA20150065A1 (fr) | Nouveaux dérivés d'acide indanyloxydihydrobenzofurannylacétique et leur utilisation comme agonistes du récepteur gpr40 | |
| MA30718B1 (fr) | Derives de pyridin-4-yle en tant qu'agents immunomodulateurs. | |
| BRPI0715579A2 (pt) | "composto, composição farmacêutica e uso de um composto" | |
| MA41107B1 (fr) | Compositions anti-cancéreuses | |
| MA33405B1 (fr) | Anticorps anti-axl | |
| WO2007027941A3 (fr) | Compositions et methode de preparation de medicaments a faible solubilite dans l'eau presentant une stabilite accrue | |
| MA29723B1 (fr) | Composes | |
| EP2588116A4 (fr) | Formulations d'une solution intraveineuse de posaconazole stabilisées par une cyclodextrine bêta substituée | |
| WO2007139815A3 (fr) | Procédé d'imagerie et de thérapie utilisant des cellules progénitrices | |
| WO2011053901A3 (fr) | Nanostructures magnetiques utilisees en tant qu'agents theranostiques | |
| MA31623B1 (fr) | Nouveaux herbicides | |
| MA34981B1 (fr) | Formulations comprenant 2-amino-2-2-4-octylphenyl)ethyl)propane-1,3-diol | |
| EP2365974A4 (fr) | Dérivés de benzothiazole fluorés, préparation de ceux-ci et agent d'imagerie utilisant ces dérivés pour diagnostiquer la maladie d'alzheimer | |
| Wang et al. | Protease‐Activatable Hybrid Nanoprobe for Tumor Imaging | |
| MA33463B1 (fr) | Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique | |
| MA31565B1 (fr) | Estratriènes à substitution 8-bêta servant d'oestrogènes sélectivement actifs | |
| AR059741A1 (es) | Formulaciones farmaceuticas liquidas y semisolidas y procedimientos | |
| Langone et al. | Coupling to a cancer cell‐specific antibody potentiates tumoricidal properties of curcumin | |
| CO6280503A2 (es) | Conjugados de neurturina novedosas para uso farmaceutico |